Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.68 |
| ▸ | CCND1 | P24385 | 17/20 | 0.68 |
| ▸ | CCND2 | P30279 | 14/20 | 0.68 |
| ▸ | CCND3 | P30281 | 14/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | STK16 | O75716 | 1/20 | 0.55 |
| ▸ | CCNK | O75909 | 1/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874473 | 0.91 | CDK4 (0.75) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL2074567 | 0.89 | CDK4 (0.75) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL29615455 | 0.89 | CDK4 (0.75) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL6225583 | 0.89 | CDK4 (0.66) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4832839 | 0.88 | CDK4 (0.61) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL18650331 | 0.87 | CDK4 (0.68) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4828673 | 0.86 | CDK4 (0.71) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL27667901 | 0.84 | CDK4 (0.75) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4835778 | 0.83 | CDK4 (0.71) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4830656 | 0.82 | CDK4 (0.88) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | claimed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| US-7456168-B2 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2008-11-25 | — | — | US | claimed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | claimed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | claimed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | claimed |
| US-20230118053-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2016024232-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| US-7456168-B2 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CDK4 1/4885CCND1 27/4885CCND2 33/4885 |
| US-20230118053-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | CDK6, CDK4, CDK2 | CDK4 2/4885CCND1 55/4885CCND2 42/4885 |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 35/4885CCND2 37/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CDK4 1/4885CCND1 34/4885CCND2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.